BlackRock
NBSE

BlackRock’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

BlackRock’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-84
Closed -$62 – 5422
2023
Q4 		$62 Sell
84
-356
-81% -$260 ﹤0.01% 5339
2023
Q3 		$383 Sell
440
-24
-5% -$29 ﹤0.01% 5361
2023
Q2 		$868 Sell
464
-3,355
-88% -$11.1K ﹤0.01% 5413
2023
Q1 		$14.1K Buy
3,819
+101
+3% +$466 ﹤0.01% 5289
2022
Q4 		$14.1K Buy
3,718
+62
+2% +$318 ﹤0.01% 5419
2022
Q3 		$29K Sell
3,656
-104
-3% -$1.72K ﹤0.01% 5456
2022
Q2 		$80K Sell
3,760
-11
-0.3% -$258 ﹤0.01% 5301
2022
Q1 		$141K Sell
3,771
-155
-4% -$5.36K ﹤0.01% 5201
2021
Q4 		$220K Sell
3,926
-160
-4% -$10.7K ﹤0.01% 5087
2021
Q3 		$295K Sell
4,086
-262
-6% -$20.1K ﹤0.01% 4888
2021
Q2 		$416K Sell
4,348
-42,122
-91% -$4.65M ﹤0.01% 4738
2021
Q1 		$6.87M Buy
46,470
+8
+0% +$1.45K ﹤0.01% 3791
2020
Q4 		$6.5M Buy
46,462
+1,147
+3% +$186K ﹤0.01% 3583
2020
Q3 		$6.88M Sell
45,315
-1,318
-3% -$215K ﹤0.01% 3434
2020
Q2 		$8.19M Buy
46,633
+44,030
+1,692% +$7.37M ﹤0.01% 3298
2020
Q1 		$371K Hold
2,603
– – ﹤0.01% 4117
2019
Q4 		$375K Buy
2,603
+1,565
+151% +$184K ﹤0.01% 4210
2019
Q3 		$104K Hold
1,038
– – ﹤0.01% 4437
2019
Q2 		$71K Hold
1,038
– – ﹤0.01% 4539
2019
Q1 		$47K Buy
1,038
+1
+0.1% +$48 ﹤0.01% 4486
2018
Q4 		$35K Buy
1,037
+4
+0.4% +$290 ﹤0.01% 4521
2018
Q3 		$77K Buy
1,033
+1
+0.1% +$75 ﹤0.01% 4492
2018
Q2 		$81K Buy
1,032
+3
+0.3% +$262 ﹤0.01% 4492
2018
Q1 		$91K Sell
1,029
-18
-2% -$2.68K ﹤0.01% 4355
2017
Q4 		$779K Buy
1,047
+2
+0.2% +$772 ﹤0.01% 3966
2017
Q3 		$301K Buy
1,045
+3
+0.3% +$819 ﹤0.01% 4149
2017
Q2 		$267K Sell
1,042
-264
-20% -$70.9K ﹤0.01% 4184
2017
Q1 		$435K Buy
+1,306
New +$605K ﹤0.01% 4002

Other funds holding NBSE

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

BlackRock's NBSE Position: Q1 2024 in Review

BlackRock sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2024, closing a stake of 84 shares — an estimated $62 sold.

BlackRock first reported a position in NBSE in Q1 2017 and held it in 28 quarters. The position peaked at $8.19M in Q2 2020. 19 funds tracked by Wall St. Rank hold NBSE as of Q1 2024.

  • BlackRock reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 84 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $62.
  • BlackRock first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2017 and held it in 28 quarters.
  • BlackRock's NeuBase Therapeutics, Inc. Common Stock position peaked at $8.19M in Q2 2020.
  • 19 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.